IRAK1 and hepatocellular carcinoma: It was previously shown that IRAK1, in the TLR/IRAK pathway, is significantly upregulated in hepatocellular carcinoma (HCC) and may promote self-renewal, tumorigenicity, and liver tumor-initiating cell marker expression.